Capricor Therapeutics (CAPR) Change in Account Payables (2010 - 2023)
Capricor Therapeutics (CAPR) posted quarterly Change in Account Payables of $7302.0 for Q4 2023, up 43.8% year-over-year from $5078.0 in Q4 2022, and up 371.1% quarter-over-quarter from $1550.0 in Q3 2023.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Change in Account Payables (2010 - 2023) Analysis & Trends
Capricor Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at $7302.0 for Q4 2023.
- In Q4 2023, Change in Account Payables rose 43.8% year-over-year to $7302.0; the TTM figure through Dec 2023 stood at -$61755.0 (up 87.89% YoY), while the FY2023 annual figure was -$61755.0, up 87.89% from the prior year.
- Change in Account Payables for Q4 2023 stood at $7302.0, up from $1550.0 in the prior quarter.
- The five-year high for Change in Account Payables was $312362.0 in Q1 2021, with the low at -$480713.0 in Q2 2022.
- The 3-year median for Change in Account Payables is $3314.0 (2022), against an average of $1542.2.
- The sharpest annual moves came in 2022 and 2023: Change in Account Payables sank 985.01% in 2022, then jumped 115.53% in 2023.
- Capricor Therapeutics' Change in Account Payables stood at $102308.0 in 2021, then slumped by 95.04% to $5078.0 in 2022, then soared by 43.8% to $7302.0 in 2023.
- Business Quant data shows CAPR's Change in Account Payables at $7302.0 in Q4 2023, $1550.0 in Q3 2023, and -$89.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 7,302.00 |
| Sep 30, 2023 | 1,550.00 |
| Jun 30, 2023 | -89.00 |
| Mar 31, 2023 | -70,518.00 |
| Dec 31, 2022 | 5,078.00 |
| Sep 30, 2022 | -9,979.00 |
| Jun 30, 2022 | -480,713.00 |
| Mar 31, 2022 | -24,540.00 |
| Dec 31, 2021 | 102,308.00 |
| Sep 30, 2021 | 121,429.00 |
| Jun 30, 2021 | 54,317.00 |
| Mar 31, 2021 | 312,362.00 |
| Jun 30, 2014 | -51,818.00 |
| Mar 31, 2014 | 9,963.00 |
| Dec 31, 2013 | 151,079.00 |
| Sep 30, 2013 | -41,151.00 |
| Jun 30, 2013 | -22,379.00 |
| Mar 31, 2013 | 9,963.00 |
| Dec 31, 2012 | 227,787.00 |
| Sep 30, 2012 | 88,331.00 |